| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Thilo van Eimeren, Bénédicte Ballanger, Giovanna Pellecchia, Janis M Miyasaki, Anthony E Lang, Antonio P Strafell. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 13. 2010-01-19. PMID:19741594. |
we tested the hypothesis that tonic stimulation of dopamine receptors specifically desensitizes the dopaminergic reward system by preventing decreases in dopaminergic transmission that occurs with negative feedback. |
2010-01-19 |
2023-08-12 |
Not clear |
| Werner J Geldenhuys, Lois-May Bezuidenhout, Dean E Dluze. Effects of a novel dopamine uptake inhibitor upon extracellular dopamine from superfused murine striatal tissue. European journal of pharmacology. vol 619. issue 1-3. 2010-01-14. PMID:19686731. |
the dopamine transporter (dat) plays an important role in substance abuse, schizophrenia, and dopaminergic toxicity associated with the parkinsonian animal model toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp). |
2010-01-14 |
2023-08-12 |
Not clear |
| Werner J Geldenhuys, Lois-May Bezuidenhout, Dean E Dluze. Effects of a novel dopamine uptake inhibitor upon extracellular dopamine from superfused murine striatal tissue. European journal of pharmacology. vol 619. issue 1-3. 2010-01-14. PMID:19686731. |
we have been working with a novel cage compound, 8-phenylethyl-pentacycloundecane , and found that this compound can inhibit dopamine uptake and serve as a neuroprotectant against mptp-induced dopaminergic toxicity. |
2010-01-14 |
2023-08-12 |
Not clear |
| Werner J Geldenhuys, Lois-May Bezuidenhout, Dean E Dluze. Effects of a novel dopamine uptake inhibitor upon extracellular dopamine from superfused murine striatal tissue. European journal of pharmacology. vol 619. issue 1-3. 2010-01-14. PMID:19686731. |
these data demonstrate that compound 1 modulates dopaminergic function as determined by effects upon extracellular dopamine responses. |
2010-01-14 |
2023-08-12 |
Not clear |
| Marten P Smidt, J Peter H Burbac. A passport to neurotransmitter identity. Genome biology. vol 10. issue 7. 2010-01-13. PMID:19591649. |
comparison of a regulatory network that specifies dopaminergic neurons in caenorhabditis elegans to the development of vertebrate dopamine systems in the mouse reveals a possible partial conservation of such a network. |
2010-01-13 |
2023-08-12 |
mouse |
| Veronica I Brito, Verena E Rozanski, Cordian Beyer, Eva Küpper. Dopamine regulates the expression of the glutamate transporter GLT1 but not GLAST in developing striatal astrocytes. Journal of molecular neuroscience : MN. vol 39. issue 3. 2010-01-12. PMID:19685014. |
since dopamine plays a crucial role for the early transmitter-regulated differentiation of striatal gabaergic neurons, we emphasized that dopaminergic transmission may also be involved in the fine tuning of intra-striatal glutamate action. |
2010-01-12 |
2023-08-12 |
Not clear |
| Francesco Roselli, Nicola M Pisciotta, Robert Perneczky, Michele Pennelli, Maria S Aniello, Maria F De Caro, Ermanno Ferrannini, Bruno Tartaglione, Giovanni Defazio, Giuseppe Rubini, Paolo Livre. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Movement disorders : official journal of the Movement Disorder Society. vol 24. issue 14. 2010-01-12. PMID:19705471. |
dopamine transporter (dat) imaging with (123)i-labeled ligand n-delta-(fluoropropyl)-2 beta-carbomethoxy-3beta-(4-iodophenyl)tropene ((123)i-fp-cit), which reliably measures midbrain dopaminergic dysfunction, has provided important evidence on the neurobiological substrate of some of these symptoms including apathy and depression. |
2010-01-12 |
2023-08-12 |
Not clear |
| Mei-Fang Xiao, Jin-Chong Xu, Yuliya Tereshchenko, Daniel Novak, Melitta Schachner, Ralf Kleen. Neural cell adhesion molecule modulates dopaminergic signaling and behavior by regulating dopamine D2 receptor internalization. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 29. issue 47. 2010-01-12. PMID:19940170. |
neural cell adhesion molecule modulates dopaminergic signaling and behavior by regulating dopamine d2 receptor internalization. |
2010-01-12 |
2023-08-12 |
mouse |
| Mei-Fang Xiao, Jin-Chong Xu, Yuliya Tereshchenko, Daniel Novak, Melitta Schachner, Ralf Kleen. Neural cell adhesion molecule modulates dopaminergic signaling and behavior by regulating dopamine D2 receptor internalization. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 29. issue 47. 2010-01-12. PMID:19940170. |
the dopaminergic system plays an important role in the etiology of schizophrenia, and most antipsychotic drugs exert their functions by blocking dopamine d(2) receptors (d(2)rs). |
2010-01-12 |
2023-08-12 |
mouse |
| Yuki Hayashida, Carolina Varela Rodríguez, Genki Ogata, Gloria J Partida, Hanako Oi, Tyler W Stradleigh, Sherwin C Lee, Anselmo Felipe Colado, Andrew T Ishid. Inhibition of adult rat retinal ganglion cells by D1-type dopamine receptor activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 29. issue 47. 2010-01-12. PMID:19940196. |
dopaminergic interneurons synapse onto cells that route signals to mammalian retinal ganglion cells, but it is unknown whether dopamine can activate receptors in these ganglion cells and, if it does, how this affects their excitability. |
2010-01-12 |
2023-08-12 |
rat |
| Louisa C Johnston, Jamie Eberling, Philip Pivirotto, Piotr Hadaczek, Howard J Federoff, John Forsayeth, Krystof S Bankiewic. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Human gene therapy. vol 20. issue 5. 2010-01-11. PMID:19203243. |
aav2-gdnf gene transfer does not appear to elicit adverse effects, delivers therapeutic levels of gdnf within target brain areas, and enhances utilization of striatal dopamine and dopaminergic nigrostriatal innervation. |
2010-01-11 |
2023-08-12 |
human |
| Jamie L Eberling, Adrian P Kells, Philip Pivirotto, Janine Beyer, John Bringas, Howard J Federoff, John Forsayeth, Krystof S Bankiewic. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Human gene therapy. vol 20. issue 5. 2010-01-11. PMID:19254173. |
these findings are consistent with our previous report in aged nonhuman primates that showed evidence of enhanced use of striatal dopamine and dopaminergic nigrostriatal innervation. |
2010-01-11 |
2023-08-12 |
human |
| Przemysław Nowak, Lukasz Noras, Jerzy Jochem, Ryszard Szkilnik, Halina Brus, Eva Körossy, Jacek Drab, Richard M Kostrzewa, Ryszard Bru. Histaminergic activity in a rodent model of Parkinson's disease. Neurotoxicity research. vol 15. issue 3. 2010-01-08. PMID:19384597. |
rats lesioned shortly after birth with 6-ohda have been proposed to be a near-ideal model of severe parkinson's disease, because of non-lethality of the procedure, near-total destruction of nigrostriatal dopaminergic fibers, and near-total dopamine (da) denervation of striatum. |
2010-01-08 |
2023-08-12 |
rat |
| Oscar Arias-Carrión, Ti-Fei Yua. Autologous neural stem cell transplantation: a new treatment option for Parkinson's disease? Medical hypotheses. vol 73. issue 5. 2010-01-04. PMID:19467573. |
the clinical motor dysfunction in parkinson s disease (pd) is primarily linked to the depletion of dopamine in the striatum consecutive to the loss of the large dopaminergic neurons in the substantia nigra. |
2010-01-04 |
2023-08-12 |
human |
| S Arpin, E Lagrue, S Bodard, S Chalon, P Castelna. Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study. Metabolic brain disease. vol 24. issue 3. 2009-12-30. PMID:19789969. |
the membrane dopamine transporter (dat) density, which provides a reliable index of dopaminergic neurons survival in the basal ganglia, was assessed by semi-quantitative autoradiography of the striatum. |
2009-12-30 |
2023-08-12 |
mouse |
| Alfonso Abizai. Ghrelin and dopamine: new insights on the peripheral regulation of appetite. Journal of neuroendocrinology. vol 21. issue 9. 2009-12-21. PMID:19523165. |
moreover, vta dopamine neurones increase their activity in response to ghrelin in slice preparations, suggesting that ghrelin increases food intake by modulating the activity of dopaminergic neurones in the vta. |
2009-12-21 |
2023-08-12 |
Not clear |
| Celine Ullrich, Christian Humpe. The pro-apoptotic substance thapsigargin selectively stimulates re-growth of brain capillaries. Current neurovascular research. vol 6. issue 3. 2009-12-14. PMID:19534719. |
nerve fibers of cholinergic nbm neurons grew into the cortex and dopaminergic nerve fibers sprouted into dopamine d2 receptor-positive dstr. |
2009-12-14 |
2023-08-12 |
Not clear |
| S Scheggi, A Crociani, M G De Montis, A Tagliamonte, C Gambaran. Dopamine D1 receptor-dependent modifications in the dopamine and cAMP-regulated phosphoprotein of Mr 32 kDa phosphorylation pattern in striatal areas of morphine-sensitized rats. Neuroscience. vol 163. issue 2. 2009-12-14. PMID:19559764. |
this tonic increase in dopamine d(1) dopaminergic transmission is counter-adaptive to an enhanced mu-opioid receptor-dependent signaling in striatal areas. |
2009-12-14 |
2023-08-12 |
rat |
| Tali Fishman-Jacob, Lydia Reznichenko, Moussa B H Youdim, Silvia A Mande. A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A. The Journal of biological chemistry. vol 284. issue 47. 2009-12-14. PMID:19748892. |
skp1a silencing resulted in increased susceptibility to neuronal damages induced by the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium ion and serum starvation, in parallel with a decline in the expression of the dopaminergic markers, dopamine transporter and vesicular monoamine transporter-2. |
2009-12-14 |
2023-08-12 |
mouse |
| Ariane Park, Mark Stac. Non-motor symptoms in Parkinson's disease. Journal of neurology. vol 256 Suppl 3. 2009-12-11. PMID:19711119. |
treatment may include interventions independent of traditional, dopaminergic anti-parkinson therapy or may be tailored to increase or reduce dopamine responsiveness of the symptom. |
2009-12-11 |
2023-08-12 |
Not clear |